Cetuximab combined with paclitaxel or paclitaxel alone for patients with recurrent or metastatic head and neck squamous cell carcinoma progressing after EXTREME

BACKGROUND: Prognosis of recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) remains poor. The addition of cetuximab, to platinum and fluorouracil chemotherapy (EXTREME regimen) has been shown to improve patients’ outcomes in first‐line settings. METHODS: We conducted a retro...

Descripción completa

Detalles Bibliográficos
Autores principales: Chevalier, Thomas, Daste, Amaury, Saada‐Bouzid, Esmaa, Loundou, Anderson, Peyraud, Florent, Lambert, Tiphaine, Le Tourneau, Christophe, Peyrade, Frédéric, Dupuis, Charlotte, Alfonsi, Marc, Fayette, Jérôme, Reure, Juliette, Huguet, Florence, Fakhry, Nicolas, Toullec, Clémence, Salas, Sébastien
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8209557/
https://www.ncbi.nlm.nih.gov/pubmed/34080776
http://dx.doi.org/10.1002/cam4.3953

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8209557/
https://www.ncbi.nlm.nih.gov/pubmed/34080776
http://dx.doi.org/10.1002/cam4.3953

Ejemplares similares